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From its Diuretic and Potassium-Sparing Effects
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Infarction Heart Failure Efficacy and Survival Study) Substudy
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Objectives The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with
eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS
(Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n  6,080) and whether
this was associated with eplerenone’s beneficial effects on cardiovascular outcomes.
Background The mechanism of the survival benefit of eplerenone in patients with heart failure post-myocardial infarction
remains uncertain.
Methods A diuretic effect was indirectly estimated by changes at 1 month that was superior to the median changes in the
placebo group in body weight (0.05 kg) and in the estimated plasma volume reduction (1.4%). A potassium-
sparing effect was defined as a serum potassium increase greater than the median change in the placebo
group: 0.11 mmol/l.
Results In the eplerenone group, body weight (p  0.0001) and plasma volume (p  0.047) decreased, whereas blood
protein and serum potassium increased (both, p  0.0001), as compared with the placebo group, suggesting a
diuretic effect induced by eplerenone, associated with a potassium-sparing effect. A diuretic effect, as defined by
an estimated plasma volume reduction, was independently associated with 11% to 19% better outcomes (lower
all-cause death, cardiovascular death or cardiovascular hospitalization, all-cause death or hospitalization, hospi-
talization for heart failure). Potassium sparing was also independently associated with 12% to 34% better out-
comes. There was no statistically significant interaction between the observed beneficial effects of eplerenone
(9% to 17%) on cardiovascular outcomes and potassium-sparing or diuretic effects.
Conclusions Eplerenone’s beneficial effects on long-term survival and cardiovascular outcomes are independent from early
potassium-sparing or diuretic effects, suggesting that mineralocorticoid receptor antagonism provides cardiovas-
cular protection beyond its diuretic and potassium-sparing properties. (J Am Coll Cardiol 2011;58:1958–66)
© 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2011.04.049S
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tAlthough recommended by current congestive heart failure
(HF) management guidelines, long-term diuretic use is still
a matter of controversy, since it may be associated with
worse prognosis and is not supported by large-scale, ran-
domized controlled studies. However, congestion is associ-
ated with worse outcome in patients with HF (1–3). The
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EPHESUS (Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival) study demonstrated
that the addition of a low dose of the mineralocorticoid
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November 1 2011:1958–66 Eplerenone Diuretic Effect in an EPHESUS Substudyreceptor blocker eplerenone to standard medical therapy
(including diuretics) in patients with acute myocardial
infarction and HF with left ventricular systolic dysfunction
improved survival by 15%, with significant reductions in
cardiovascular death, sudden death, and hospitalization for
heart failure (4). In addition to a variety of pleiotropic effects
(5), eplerenone may exert a diuretic, as well as a potassium
(K)-sparing effect. The aim of the present study was to
determine whether a diuretic and/or a K-sparing effect
could be detected in patients treated with eplerenone in an
EPHESUS substudy and, if any, whether these effects
influenced cardiovascular outcomes.
Methods
Study design and patient population. The design and
main results of the EPHESUS trial have been reported
previously (4). The EPHESUS study enrolled patients with
HF following acute myocardial infarction complicated by
left ventricular systolic dysfunction (ejection fraction
40%). Heart failure had to be documented by at least 1 of
the following: presence of pulmonary rales, chest radiogra-
phy showing pulmonary venous congestion, or the presence
of a third heart sound. Patients were entered into the study
at any point from 3 to 14 days after the infarction. Patients
with diabetes mellitus were not required to have evidence of
HF. Among patients with biological assessment at month 1,
32% had diabetes (placebo vs. eplerenone: 32% vs. 32%).
Only 4 diabetic patients (0.2%) had a left ventricular
ejection fraction 40% at inclusion. The mean ejection
Figure 1 Flow Chart: Substudy Population
EPHESUS  Eplerenone Post-Acute Myocardial Infarction Heart Failure
Efficacy and Survival study.fraction was 32.6  6.2% in di-
abetic patients versus 33.6 
5.9% in nondiabetic patients
(p  0.0001). All patients were
randomly assigned to treatment
with eplerenone 25 mg/day or
placebo for the first month and
up-titrated to 50 mg/day or pla-
cebo, depending on serum K lev-
els. Treatment with eplerenone
was in addition to standard med-
ical therapy, which could include angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers, beta-
blockers, diuretics, aspirin, or statins, as well as coronary
reperfusion therapy. EPHESUS was an event-driven study,
and the mean duration of follow-up was 16 months.
Among the 6,632 patients enrolled in the EPHESUS
study, 552 were excluded from the present analysis because
of unavailable data at month 1 (259 [47%] died before 5
weeks, and 293 [53%] did not have the clinical and/or
biological data requested for the diuretic-like effect assess-
ment as defined later in the text). Therefore, 6,080 patients
were included in our substudy (placebo: n  3,025; epler-
enone: n  3,055) (Fig. 1), among which 5,692 were
assessed at month 3 (placebo: n  2,837; eplerenone: n 
,855). Moreover, 351 patients were tested for brain natri-
retic peptide (BNP) (Biosite, San Diego, California) at
aseline and at month 1, as previously reported (6).
stimation of the diuretic effect. A diuretic effect was
efined post-hoc using 6 working definitions, with cutoffs
aken as the medians observed in the placebo group:
. Weight reduction 0.05 kg at 1 month
. Estimated plasma volume reduction 1.4% at 1 month
(plasma volume reduction was indirectly estimated using
the Strauss formula (7,8):
% change in plasma volume 
100
hemoglobin (before)
hemoglobin (after)

1 hematocrit (after)
1 hematocrit (before)
 100
We have also tested protidemia increase 4 g/l at 1
month as well as various combinations of any 2 of these
tentative definitions, and we found these other definitions to
be redundant (see the Results section). A K-sparing effect
was defined as a change from baseline greater than the
median change in the placebo group, that is, 0.11
mmol/l. Dosage in furosemide equivalent doses (milli-
grams/day) for patients on loop diuretics were calculated as
follows: 40-mg furosemide  1-mg bumetanide  10-mg
piretanide  10-mg torsemide (9).
Statistical analysis. All analyses were performed using
SAS version 9.1.3 release (SAS Institute, Cary, North Caro-
lina). The 2-tailed significance level was set to p  0.05.
Continuous variables were described as mean  SD, and
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
eGFR  estimated
glomerular filtration rate
HF  heart failure
MRA  mineralocorticoid
receptor antagonistcategorical data as frequency (percent). Comparisons of
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Eplerenone Diuretic Effect in an EPHESUS Substudy November 1 2011:1958–66treatment groups were carried out using the Mann-Whitney
U test. Changes in the 2 treatment groups between baseline
and 1 month on the one hand and between 1 and 3 months
on the other hand were assessed using the group  time
interaction of repeated measures analysis of variance. These
changes were graphically presented as unadjusted means at
baseline, 1 month, and 3 months for patients with available
data at baseline and 1 month for the first period, and at 1
and 3 months for the second. Correlation analyses into the
subsample of patients with available biomarkers data were
carried out using the Spearman correlation method. Asso-
ciation of crude rates of outcomes with quintiles of 1-month
estimated plasma volume change from baseline was illus-
trated by plotting appropriate histograms; the trend analyses
between quintiles and outcomes were performed using the
Cochran-Armitage test. Because clinical signs of pulmonary
congestion were not required in diabetic patients, interac-
tion between diabetes and treatment group was additionally
tested using the Breslow-Day test for K and plasma volume
responses.
Time-to-event analyses, using 6 adjudicated outcomes—
all-cause death (first primary endpoint), cardiovascular
death or cardiovascular hospitalization (second primary
endpoint), cardiovascular death, all-cause death or hospital-
ization, hospitalization for heart failure progression, or
sudden death—were carried out in 1-month survivors, using
the Cox proportional hazards model with an interactive
backward selection method. Nine factors were tested as
potentially associated with the outcomes: study drug, di-
uretic effect (see previous text), K-sparing effect, age at
baseline, baseline K, baseline estimated glomerular filtration
rate (eGFR) as assessed by the MDRD (Modification of
Diet in Renal Disease) formula (10), eGFR change from
baseline to 1 month, baseline mean blood pressure, and
mean blood pressure change at 1 month. Study drug and
diuretic effect were forced in all the models. All the validity
assumptions of the Cox model were thoroughly checked
(proportional hazards, log-linearity of the association be-
tween continuous covariables and risk, absence of interac-
tion or collinearity). The covariables that did not meet the
log-linearity assumption were dichotomized according to
the median in the placebo group (estimated plasma
volume and K change, see the previous text), or the shape
of the curve when possible (mean blood pressure [MBP]
and MBP change) or entered into the model as stratifi-
cation factors otherwise. Additionally, estimated plasma
volume and K changes were analyzed by quintiles in order
to check that entering them as binary variables did not
exclude some of their explanatory power and artificially
inflated the estimated drug effect. Results were expressed
as hazard ratios (95% confidence interval [CI]) and
graphically presented as forest plots. Except for the main
exposition factors (study drug, estimated plasma volume,
and K effects), only significant covariables were retained in the
final Cox models and displayed on graphic presentations. wResults
The main patient features in this EPHESUS substudy are
presented in Table 1. No significant difference was found
between treatment groups. Compared with the remaining
EPHESUS population, the 552 patients excluded because of
unavailable data at month 1 were generally older and sicker.
Eplerenone exerts early diuretic-like and K-sparing effects.
Body weight (placebo: 78 15 kg vs. eplerenone: 79 15 kg
[p  0.38]) and protidemia (placebo: 69  7 g/l vs.
plerenone 68 7 g/l [p 0.74]) did not significantly differ
at baseline between the study groups (Figs. 2A and 2C).
After 1 month, we observed in both study groups a
significant decrease in body weight (Fig. 2A) (p  0.0001),
an increase in plasma protein concentration (Fig. 2C) (p 
.0001), and a decrease in estimated plasma volume
Fig. 2B) (p  0.0001). These effects were of significantly
igher magnitude in the eplerenone group (Figs. 2A to 2C),
uggesting a diuretic-like effect of the study drug. This effect
ccurred early during the study, with the initiation dose of
5 mg once daily. Indeed, these differences were no longer
ignificant between the first and the third month. Actually,
espite the per-protocol up-titration to the higher dose of
0 mg once daily, plasma volume changes were of greater
agnitude in the placebo group. Interestingly, over a
-month period, neither the diuretic (besides eplerenone)
ntake (at inclusion: eplerenone [51%] vs. placebo [52%],
 0.60; at month 1: eplerenone [52%] vs. placebo [53%],
 0.66; at month 3: eplerenone [51%] vs. placebo [53%], p
.12) nor the furosemide-dose equivalent intake (for loop
iuretics) differed significantly between both groups (at
nclusion, median [extremes]: eplerenone: 40 [4 to 400] vs.
lacebo 40 [3 to 400] mg/day, p  0.69; at month 1:
plerenone: 40 [4 to 400] vs. placebo 40 [3 to 300] mg/day,
 0.47; at month 3: eplerenone 40 [4 to 375] vs. placebo
0 [3 to 240] mg/day, p  0.20).
Using the kappa statistic to assess the relationship be-
ween the various definitions of a diuretic-like effect (based
n weight decrease, protein increase, estimated plasma
olume decrease, or various combinations of these parame-
ers above the median in the placebo group), we observed
hat all of them were significantly correlated (kappa: p 
.01) besides “weight decrease” and “estimated plasma
olume decrease” (kappa: p  0.95), which were selected to
valuate the association of the cardiovascular outcomes with
he early diuretic effect. Indeed, the consistency between
eight and plasma volume changes was found to be 50%,
hich means that there was as much chance of agreement as
isagreement. The other definitions overlapped significantly
from 52% for weight/protidemia, to 66% for protidemia/
lasma volume) and were not retained in the analyses since
hey had more chance of agreement than disagreement. Inter-
stingly, in a subset of our study population tested for biomark-
rs, plasma volume changes between baseline and month 1
ere significantly correlated with BNP concentration varia-
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November 1 2011:1958–66 Eplerenone Diuretic Effect in an EPHESUS Substudytions (r  0.284; p  0.0001) independently from study drug
nd eGFR variations.
Baseline K levels did not differ significantly between patients
ssigned placebo or eplerenone (placebo: 4.3 0.4 mmol/l vs.
plerenone 4.3  0.4 mmol/l [p  0.15]) (Fig. 2D). In both
tudy groups, a significant increase in serum K concentration
as observed after 1 month (p  0.0001), and was of greater
agnitude in the eplerenone group. This effect was more
ronounced after 3 months in the eplerenone group (Fig. 2D).
n parallel, K supplements were used more than twice as often
n the placebo group, as compared with the eplerenone group
fter 3 months (9% vs. 4%, p  0.0006).
Clinical signs of pulmonary congestion were not required
at inclusion in diabetic patients, therefore interactions be-
tween diabetes and treatment group were additionally tested
with regard to the plasma volume response and to the K
response, and were not found significant (plasma volume
response: p  0.50; K response: p  0.56).
Association of estimated early plasma volume depletion
and the K-sparing effect with long-term cardiovascular
outcomes. Independently from eplerenone use, and with-
out any significant interaction, estimated plasma volume
Baseline Features of Patients With Available DataTable 1 Baseline Features of Patients With A
P
(n 
Age, yrs 6
Caucasians 2,7
Male 2,1
Blood pressure, mm Hg
Systolic 11
Diastolic 7
Left ventricular ejection fraction, % 3
Days from myocardial infarction to randomization
Previous hospitalization for heart failure 2
Reperfusion therapy/revascularization 1,4
Symptoms of heart failure 2,5
Serum potassium, mmol/l 4.
Serum creatinine mol/l 9
eGFR, ml/min/1.73 m2 6
Medical history
Acute myocardial infarction 7
Diabetes 9
Heart failure 4
Hypertension 1,8
Medications
ACEI/ARB 2,6
Beta-blockers 2,2
Diuretics 1,7
Aspirin 2,7
Statins 1,4
Digoxin 4
Amiodarone 2
Values are mean SD or n (%). No significant difference was found be
‡p  0.001.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensidepletion, as defined in the preceding text, was consistentlysignificantly associated with a 11% to 19% improvement in
most of the tested cardiovascular outcomes (all-cause death,
cardiovascular death or cardiovascular hospitalization, all-
cause death or cardiovascular hospitalization, and hospital-
ization for heart failure and a similar but nonsignificant
trend [p  0.090] for cardiovascular death), but not for
sudden death (Fig. 3). Furthermore, across the spectrum of
the tested cardiovascular outcomes (besides sudden death),
the association between the intensity of the estimated
plasma volume depletion and the crude event rates showed
a significant linear trend in the whole study population
(Fig. 4). In contrast, the weight-based definition of the
diuretic effect was not significantly associated with any of
the assessed outcomes (Fig. 3).
Independently from eplerenone use, and without any
significant interaction, the K-sparing effect was associated
with a significant 12% to 34% improvement of almost all
tested outcomes, but not to all-cause death or hospitaliza-
tion, nor to hospitalization for heart failure (Fig. 3). Similar
significant or marginally significant trends were observed
when analyzing the crude event rates (Table 2).
Multivariate analyses of the main cardiovascular outcome
onth 1 Versus Excluded Patientsle Data at Month 1 Versus Excluded Patients
1-Month Survivors
5)
Eplerenone
(n  3,055)
All
(n  6,080)
Others
(n  552)
63 11 64 12 68 11‡
%) 2,766 (91%) 5,513 (91%) 471 (85%)‡
%) 2,186 (72%) 4,346 (71%) 368 (67%)*
119 17 119 16 118 17†
72 11 72 11 71 12†
33 6 33 6 31 7‡
7 3 7 3 8 3
) 222 (7%) 457 (8%) 55 (10%)*
%) 1,405 (46%) 2,810 (46%) 196 (36%)‡
%) 2,565 (84%) 5,097 (84%) 482 (88%)*
4 4.3 0.4 4.3 0.4 4.2 0.5†
100 28 99 28 107 33‡
68 19 69 19 63 20‡
%) 839 (27%) 1,633 (27%) 170 (31%)*
%) 972 (32%) 1,936 (32%) 206 (37%)‡
%) 430 (14%) 884 (15%) 91 (16%)
%) 1,823 (60%) 3,675 (60%) 332 (60%)
%) 2,639 (86%) 5,279 (87%) 472 (86%)
%) 2,305 (75%) 4,597 (76%) 364 (66%)‡
%) 1,800 (59%) 3,594 (59%) 390 (71%)‡
%) 2,691 (88%) 5,393 (89%) 477 (86%)
%) 1,421 (47%) 2,848 (47%) 247 (45%)
%) 424 (14%) 869 (14%) 135 (24%)‡
) 224 (7%) 464 (8%) 80 (14%)‡
reatment groups in 1-month available patients. *p 0.05, †p 0.01,
tor blocker; eGFR  estimated glomerular filtration rate.at Mvailab
lacebo
3,02
4 12
47 (91
60 (71
9 16
2 11
3 6
7 3
35 (8%
05 (46
32 (84
3 0.
9 28
9 19
94 (26
64 (32
54 (15
52 (61
40 (87
92 (76
94 (59
02 (89
27 (47
45 (15
40 (8%
tween tdeterminants confirmed that the eplerenone effect on car-
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Eplerenone Diuretic Effect in an EPHESUS Substudy November 1 2011:1958–66diovascular outcomes was independent from the early di-
uretic and K-sparing effects (analyzed as binary variables
[Fig. 3]) or quintiles, data not shown), without any signif-
icant interaction. Indeed, eplerenone was associated with
significantly better outcomes concerning cardiovascular death/
hospitalization, all-cause death/hospitalization, and hospital-
ization for HF progression (Fig. 3), with nonstatistically
significant positive trends concerning the other tested out-
comes (all-cause death, cardiovascular death, sudden cardiac
death).
Discussion
Our results show, for the first time to our knowledge, that
in patients with HF and left ventricular systolic dysfunction
complicating myocardial infarction, an initial and short-
term diuretic-like effect, as defined by an estimated plasma
volume decrease after 1 month, was associated with better
cardiovascular outcomes. This occurred independently from
a K-sparing effect, which was also associated with better
Figure 2 Eplerenone Exerts Early (1-Month) Diuretic-Like and K
Diuretic-like (A to C) and K-sparing (D) effects are shown. As a result of missing d
values are those for patients with available data at both ends of the period. Chan
values were set to zero for the graphical presentation. Change  group: interactio
variance). ePV  estimated plasma volume; M0  inclusion; M1  month 1; M3outcomes. Although these diuretic-like and K-sparing ef-fects were more pronounced with eplerenone, the benefit of
eplerenone on outcomes was independent from the diuretic
and K-sparing effects in the multivariate models. Thus,
although our results suggest that a diuretic-like effect and a
K-sparing effect of eplerenone can be detected in EPHESUS, the
benefit of eplerenone on cardiovascular outcomes cannot be
solely explained by these effects, suggesting additional pro-
tective cardiovascular pleiotropic effects of eplerenone.
Our results showing a beneficial effect of estimated
plasma volume reduction are in accordance with growing
evidence that hypervolemia by itself is independently asso-
ciated with mortality in HF patients (1–3). More specifi-
cally, Androne et al. (11) showed that an increased blood
volume, as assessed by intravenous administration of iodine-
131–labeled albumin, was associated with an increased risk
of death or urgent cardiac transplantation during a median
follow-up of 719 days (1-year event-rate: 39% vs. 0%, p 
.01). A meta-analysis of 3 small-sized (N  221), short-
term follow-up (4 to 52 weeks), randomized controlled trials
ring Effects
requencies did not sum to 6,080 (M1) nor 5,692 (M3). M0-M1 and M1-M3 mean
1: single comparison of plasma volume change (Mann-Whitney test). Baseline
een change from M1 to M3 and study group (repeated measures analysis of
th 3.-Spa
ata, f
ge at M
n betw
 monof diuretic therapy in patients with HF showed a 65%
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November 1 2011:1958–66 Eplerenone Diuretic Effect in an EPHESUS Substudyreduction in mortality under diuretic therapy. If RALES
(Randomized Aldactone Evaluation Study) (12) was also
included, the overall odds ratio was 0.61 (95% CI: 0.50 to
0.74; p  0.0001) (13). However, a variety of pathophysi-
ological mechanisms suggest that diuretics may contribute
to an increased mortality risk. Loop diuretics may activate
the renin-angiotensin aldosterone and sympathetic nervous
systems, and are associated with a decrease in the eGFR
(14). Eshaghian et al. (14) reported in a survey of 1,354
consecutive patients with advanced systolic HF an indepen-
Figure 3 Determinants of the Cardiovascular Outcomes
Relationships of variables with outcomes are shown with the assessment of a diu
plasma volume changes (lower half of each plot) added into the model. Weight D
indicates estimated plasma volume–based diuretic-like effect (included in the low
fication of Diet in Renal Disease) 10 ml/min/1.73 m2 indicates a decrease betw
mula 10 ml/min/1.73 m2. Covariables were removed from the models when the
meet the models validity assumptions. BL  baseline; MBP  mean blood pressudent dose-dependent association between loop diuretic useand impaired survival. In post hoc analyses of the PRAISE
(Prospective Randomized Amlodipine Survival Evaluation)
study (15) in 1,153 patients with advanced HF, as well as in
the ESCAPE (Evaluation Study of Congestive Heart Fail-
ure and Pulmonary Artery Catheter Effectiveness) trial
(16,17), which enrolled 433 patients with severe chronic
HF, high diuretic doses were independently associated with
mortality.
That an early estimated plasma volume decrease, but not
an extracellular and intracellular fluid volume depletion (i.e.,
ffect either by body weight changes (upper half of each plot) or by estimated
cates weight-based diuretic-like effect (included in the upper panels); ePV DLE
els). Potassium response indicates the potassium-sparing effect; 2MDRD (Modi-
clusion and month 1 in estimated glomerular filtration rate using the MDRD for-
ot reach significance or have to be used as stratification factors in order toretic e
LE indi
er pan
een in
y did n
re.weight decrease), was associated with better cardiovascular
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Eplerenone Diuretic Effect in an EPHESUS Substudy November 1 2011:1958–66outcomes, may suggest that short-term interventions that
decrease volemia may provide long-term benefits on out-
comes, in addition to symptoms. Our data therefore cor-
roborate the hypothesis of Cotter et al. (18), which suggests
that “in patients with predominantly acute cardiovascular
failure, fluid overload, mostly in the form of pulmonary
congestion, is caused by fluid redistribution rather than by
fluid accumulation.” In this setting, studies examining the
effect of vasodilators in patients with acute HF showed
beneficial effects (18–20). Although a persistent increase in
body weight after hospitalization for worsening HF is
predictive of repeat hospitalization (21), weight loss in
patients with acute HF may not be associated with im-
Figure 4 Association Between Quintiles of ePV Changes at Mo
in the Whole Study Population
ePV  estimated plasma volume changes from baseline to month 1.proved symptoms or better outcome (18,22).Potassium is an important determinant of myocardial
function, and low serum K may cause arrhythmias and
sudden cardiac death (23). Another major finding of the
present study is that an early K-sparing effect, consistent
with its mineralocorticoid receptor antagonistic effects, was
significantly associated with improved long-term cardiovas-
cular outcomes. Mineralocorticoid receptor antagonism
(MRA) on top of standard medical care including
angiotensin-converting enzyme inhibitors (or angiotensin
receptor blockers) and beta-blockers has been adopted into
both U.S. (24) and European (9) guidelines as a class I
recommendation for the treatment of post-myocardial in-
farction HF. Many clinicians, however, are hesitant to use
and the Cardiovascular Outcomes,nth 1MRAs because of concerns about hyperkalemia as an
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that the selective MRA eplerenone, when administered at a
dose of 25 to 50 mg/day, is associated with a 4.4% absolute
increase in the incidence of hyperkalemia (5.5 mEq/l) and
a 1.6% absolute increase in the incidence of more marked
hyperkalemia (6.0 mEq/l) that were not associated with
outcomes at 30 days (p 0.11) (25). The present data show
that although an early rise in K was observed in the whole
study population, it was more pronounced in patients
receiving eplerenone (although K supplements were used
more than twice as often in the placebo group) and was
associated with better cardiovascular outcomes. In contrast,
low serum K levels have been repeatedly shown to be
associated with an increased risk of mortality due to all
causes, cardiovascular causes, and progressive HF (23,26),
whereas the use of non–K-sparing diuretics is associated
with an increased risk of arrhythmic death (27).
Finally, we showed that even if eplerenone induced a
diuretic effect, its use remained significantly associated with
better cardiovascular outcomes independently from its
K-sparing effects. Therefore, our data strongly support the
hypothesis that a pleiotrophic effect of the MRA eplerenone
is involved in the pathophysiology of heart failure. These
effects may involve left ventricular (6,28) and vascular (29)
remodeling, including collagen synthesis, as well as effects
on endothelial and immune function (5).
Study limitations. We performed a post-hoc analysis,
including data-driven (median changes after 1 month in the
placebo group) definitions of diuretic-like and K-sparing
effects, since there is no consensual definition of these
effects. The diuretic-like effect was assessed by a meaningful
proposed (8) indirect estimation of plasma volume changes:
a validated (upon comparison with a radio-labeled gold
standard) method integrating hematocrit changes, which is
routinely being used to estimate plasma volumes in patients
scheduled plasma exchanges (30,31), or even ultrafiltration
in the HF setting (32), whereas of note, no specific
validation has been reported so far in the HF setting.
However, sensitivity analyses performed in a subset of our
study population showed significant positive correlations
between BNP variations (presumably mainly triggered by
variations in the level of congestion [33]) and plasma
Relationship Between the K-Sparing Effect andTable 2 Relationship Between the K-Sparing
Place
K-Sparing
No
All-cause death 12.8
All-cause death or hospitalization 53.7
CV death 11.2
CV death or hospitalization 26.7
Sudden cardiac death 5.3
Hospitalization for HF progression 13.4
The p values are treatment adjusted for association of K-sparing effec
CV  cardiovascular, HF  heart failure.volume variations. Moreover, this formula also contains phemoglobin ratios, and therefore controls for hemoglobin
changes, which may matter in HF patients, within a
cardiorenal anemia syndrome setting (34). We have elected
to describe the diuretic and K-sparing effects at 1 month
after randomization. Therefore, it is unknown whether
these effects persist throughout long-term chronic drug
exposure. Generally, long-term pharmacological effects of
diuretics are difficult to characterize. In addition, consider-
ing values at later time points would have introduced a
number of confounders and would have resulted in loss of
observations due to event occurrence or dropout, and in loss
of power and external validity. In addition, we have previ-
ously reported that the clinical benefit of eplerenone in
EPHESUS was already statistically significant at 1 month
(35). Therefore, we believe that, although partially specula-
tive, our findings and interpretations are acceptable. In any
case, stemming from a post hoc analysis, they are mainly
hypothesis generating and should be confirmed by further
investigations. Importantly, our data are derived from a
randomized controlled trial, thus allowing us to assess
reliably the association between eplerenone use and the
tested cardiovascular outcomes. However, even though we
focused our analysis on the first month of follow-up, a
minority of patients equally distributed between the 2 study
groups (overall: 8.3%; eplerenone group: 7.9%, placebo
group: 8.7%, p 0.28) could not be included in the analysis
ecause of unavailable data at month 1. In the meantime,
ithin the EPHESUS whole study population, the number
f deaths was higher (153 of 3,313, 4.6%) in the placebo
roup, compared with the eplerenone group (107 of 3,319,
.2%, p  0.003). These already reported early beneficial
ffects on mortality (35) were not taken into account in our
urvival analyses, which used a starting point of 1 month
ost-enrollment. This may have contributed to the fact that
he reported beneficial effects of eplerenone on all-cause
eath, cardiovascular death, and sudden cardiac death (4)
ere no longer found to be statistically significant in our
ubstudy.
The external validity of these results concerning pa-
ients post-myocardial infarction with HF and altered
jection fraction remains to be assessed in other patient
rude Event Ratesct and the Crude Event Rates
Eplerenone
K-Sparing Effect
es No Yes p Value
1.6 11.9 10.4 0.083
2.0 49.2 50.5 0.86
9.7 10.3 8.4 0.018
6.5 25.6 22.4 0.084
4.7 5.1 3.5 0.061
3.1 12.2 11.0 0.63
outcomes.the CEffe
bo
Effect
Y
1
5
2
1opulations.
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In the setting of HF post-myocardial infarction, our data provide
important pathophysiological insights into eplerenone’s beneficial
effects which may involve but are independent from a early
detectable significant diuretic and K-sparing effect.
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